Stockscreener 앱 받기
204.76
5.87%
11.36
시장 영업 전:
203.90
-0.86
-0.42%
Astrazeneca Plc 주식(AZN)의 최신 뉴스
Kangtai Drops Plan for China Vaccine JV With AstraZeneca - Citeline News & Insights
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
AstraZeneca (LON:AZN) Hits New 52-Week HighHere's What Happened - MarketBeat
China charges former AstraZeneca regional head Leon Wang - marketscreener.com
AstraZeneca (AZN) Faces Legal Challenges in China - GuruFocus
NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review - Benzinga
Former AstraZeneca regional head charged in China (AZN:NYSE) - Seeking Alpha
AstraZeneca And Daiichi-Sankyo Stack The Odds For Datroway’s Lung Cancer Bets - Citeline News & Insights
How AstraZeneca shot for the moon — and hit - Financial Times
China charges former AstraZeneca executive Leon Wang - marketscreener.com
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill - BioPharma Dive
AstraZeneca's ex-chief in China formally charged with insurance fraud - The Edge Malaysia
Chinese Authorities Charge AstraZeneca's Ex-China Business Head - marketscreener.com
Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipeline - Yahoo Finance UK
AstraZeneca PLC (NYSE:AZN) Q4 2025 Earnings Call Transcript - Insider Monkey
$3.4M for 47 local groups tackling care gaps, nutrition and lung disease - Stock Titan
China charges former AstraZeneca executive - Financial Times
AstraZeneca PLC (NYSE:AZN) Q4 2025 earnings call transcript - MSN
What's Driving the Market Sentiment Around AstraZeneca PLC? - Benzinga
AstraZeneca PLC (NASDAQ:AZN) Sees Significant Drop in Short Interest - MarketBeat
AstraZeneca PLC $AZN Holdings Boosted by ABC Arbitrage SA - MarketBeat
AstraZeneca to advance in-licensed oral GLP-1RA to pivotal trials - Clinical Trials Arena
Astrazeneca re-doses $80bn annual sales goal - marketscreener.com
AstraZeneca stock hits all-time high at 194.18 USD By Investing.com - Investing.com Nigeria
AstraZeneca Earnings Call Highlights Growth And Pipeline - TipRanks
AstraZeneca Q4 Earnings Call Highlights - Yahoo Finance
AstraZeneca: Q4 Earnings AnalysisTicks The Boxes, Upgrading To Buy (AZN) - Seeking Alpha
AstraZeneca Q4 and FY 2025 slides: 8% revenue growth, strategic investments for 2030 By Investing.com - Investing.com South Africa
AstraZeneca's GLP-1 pill succeeds in two mid-stage trials - TechTarget
AstraZeneca Unit Settles Soliris Feud With Samsung, Amgen - Law360
AstraZeneca PLC (NASDAQ:AZN) Announces Dividend of 1.60 - MarketBeat
AstraZeneca Keeps Its Growth Engine Moving Amid Rising Costs - Kalkine Media
Market Voices: Paramount-WBD bid, Holtec IPO, AstraZeneca - Seeking Alpha
Why Is AstraZeneca Stock Gaining Tuesday?AstraZeneca (NYSE:AZN) - Benzinga
Relaxin unrest after Astrazeneca phase II HF bid joins failures - BioWorld MedTech
AstraZeneca (AZN) Surpasses Q4 Earnings Expectations, Driven by Oncology Growth - GuruFocus
Jim Cramer on AstraZeneca: “We want every drug stock” - MSN
Oakmark International Strategy Updates Portfolio, Adds AstraZene - GuruFocus
AstraZeneca bets on continued oncology demand for 2026 growth - Pharmaceutical Technology
Jim Cramer on AstraZeneca: "We Want Every Drug Stock" - Finviz
Jim Cramer on AstraZeneca: “We Want Every Drug Stock” - Insider Monkey
Sustained By Cancer Success, AstraZeneca Is Still Sizing Up Obesity Opportunity - Citeline News & Insights
AstraZeneca profits boosted by strong cancer drug sales - Investors' Chronicle
The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026 - FinancialContent
AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook - TradingView
AstraZeneca stock hits all-time high at 194.18 USD - Investing.com
Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings - Yahoo Finance
AstraZeneca PLC $AZN Shares Purchased by Wesbanco Bank Inc. - MarketBeat
AstraZeneca PLC $AZN Shares Sold by Foresight Group Ltd Liability Partnership - MarketBeat
Oppenheimer Asset Management Inc. Increases Position in AstraZeneca PLC $AZN - MarketBeat
Earnings call transcript: AstraZeneca’s Q4 2025 revenue grows 8%, stock rises - Investing.com
AstraZeneca Targets Global Obesity Market With Low-Cost Weight-Loss Drugs - Bloomberg
AstraZeneca (AZN) Exceeds Revenue Expectations with Strong Growt - GuruFocus
Earnings snapshot: AstraZeneca beats Q4 revenue estimates; initiates FY outlook - MSN
ProShare Advisors LLC Has $50.24 Million Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca rises as cancer drugs power Q4 beat (AZN:NYSE) - Seeking Alpha
AstraZeneca forecasts steady growth in 2026 on cancer drug demand, hikes dividend - The Globe and Mail
AstraZeneca (AZN) Projects Revenue Growth and Core Tax Rate Outl - GuruFocus
AstraZeneca Upbeat on Growth as 2025 Profit, Revenue Rise Amid 'Excellent' Pipeline Delivery - Yahoo Finance UK
AstraZeneca’s growth engine stays on track despite cost pressures - Yahoo Finance
AstraZeneca Reiterates $80 Billion Revenue Goal for 2030 -- Update - marketscreener.com
AstraZeneca profit jumps as cancer drug sales grow - Yahoo Finance UK
AstraZeneca (Q4 Results): steady progress - Hargreaves Lansdown
AstraZeneca sees further growth, lifted by cancer drugs - The Edge Malaysia
AstraZeneca PLC Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
1.18%
0.70%
자본화:
|
볼륨(24시간):